List of nationally authorised medicinal products
|
|
- Byron Armstrong
- 5 years ago
- Views:
Transcription
1 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 Navelbine 50 mg/5 ml solution à diluer pour perfusion Navelbine, koncentrat til infusionsvæske, opløsning Navelbine 10 mg/ml, ενέσιμο διάλυμα Navelbine 10 mg/ml koncentrátum oldatos infúzióhoz NAVELBINE 10 mg/ml concentrato per soluzione per infusione NAVELBINE 10 mg/ml koncentrāts infūziju šķīduma pagatavošanai Navelbine 10 mg/ml koncentrat till infusionsvätska, lösning not available SAS PIERRE FABRE not available PIERRE FABRE PHARMA DK not available 41571/ PIERRE FABRE FARMAKA GR SA not available OGYI-T-4721/01 SAS PIERRE FABRE HU not available PIERRE FABRE PHARMA IT S.R.L. not available PIERRE FABRE LV not available PIERRE FABRE PHARMA SE NAVELBINE 20 mg capsules molles not available PIERRE FABRE Navelbine, bløde kapsler not available PIERRE FABRE PHARMA DK NAVELBINE 20 mg μαλακό καψάκιο not available PIERRE FABRE FARMAKA / GR GREECE NAVELBINE 20 mg capsule molli not available PIERRE FABRE PHARMA IT S.R.L. NAVELBINE 20 mg, capsule molle not available 0724/01/12/0034 PIERRE FABRE LU Navelbine, kapsułka miękka, 20 mg not available 9450 SAS PIERRE FABRE PL NAVELBINE 20 mg, cápsula mole not available PFM / PORTUGAL PT NAVELBINE 20 mg capsule moi not available 6075/2005/01 PIERRE FABRE EMA/795271/2017 Page 2/9
3 Navelbine 20 mg mjuk kapsel not available PIERRE FABRE PHARMA SE NAVELBINE 30 mg capsules molles not available PIERRE FABRE Navelbine, bløde kapsler not available PIERRE FABRE PHARMA DK NAVELBINE 30 mg μαλακό καψάκιο not available 41580/ PIERRE FABRE FARMAKA / GR GREECE NAVELBINE 30 mg capsule molli not available PFM PHARMA / ITALY IT NAVELBINE 30 mg, capsule molle not available 0724/01/12/0035 PIERRE FABRE LU Navelbine, kapsułka miękka, 30 mg not available 9451 SAS PIERRE FABRE PL NAVELBINE 30 mg, cápsula mole not available PFM / PORTUGAL PT NAVELBINE 30 mg capsule moi not available 6076/2005/01 SAS PIERRE FABRE Navelbine 30 mg mjuk kapsel not available PIERRE FABRE PHARMA SE Navelbine, bløde kapsler not available PIERRE FABRE PHARMA DK Navelbine 80 mg mjuk kapsel not available PIERRE FABRE PHARMA SE Navelbine20 mg kapsel, myk not available 02/1154 PIERRE FABRE PHARMA NO Navelbine80 mg kapsel, myk not available 02/1157 PIERRE FABRE PHARMA NO Navelbine30 mg kapsel, myk not available 02/1155 PIERRE FABRE PHARMA NO EMA/795271/2017 Page 3/9
4 Navelbine 10 mg/ml, konsentrat til not available PIERRE FABRE PHARMA NO infusjonsvæske Navelbine 50 mg/5 ml concentraat not available SAS PIERRE FABRE voor oplossing voor intraveneuze infusie NAVELBINE 30 mg capsules, zacht not available PIERRE FABRE NAVELBINE 20 mg capsules, zacht not available PIERRE FABRE Navelbine 10 mg/ml koncentrátum not available OGYI-T-4721/02 SAS PIERRE FABRE HU oldatos infúzióhoz NAVELBINE 50 mg/5 ml, solution not available 0724/ PIERRE FABRE LU NAVELBINE 30 mg capsule moi not available 6076/2005/02 PIERRE FABRE NAVELBINE 10 mg/ml concentrato not available PFM PHARMA / ITALY IT per soluzione per infusione NAVELBINE 20 mg capsule moi not available 6075/2005/02 PIERRE FABRE Navelbine 40 mg/4 ml solution à not available SAS PIERRE FABRE diluer pour perfusion Navelbine 10 mg/1 ml solution à not available SAS PIERRE FABRE diluer pour perfusion Navelbine 40 mg/4 ml concentraat not available SAS PIERRE FABRE voor oplossing voor intraveneuze infusie Navelbine 10 mg/1 ml concentraat voor oplossing voor intraveneuze infusie not available SAS PIERRE FABRE EMA/795271/2017 Page 4/9
5 Navelbine 10 mg/ml, ενέσιμο διάλυμα not available 41576/ PIERRE FABRE FARMAKA SA Navelbine 10 mg/ml, ενέσιμο not available 41578/ PIERRE FABRE FARMAKA διάλυμα SA Navelbine 10 mg/ml concentrat not available 4661/2012/02 SAS PIERRE FABRE pentru soluţie perfuzabilă Navelbine 10 mg/ml concentrat not available 4661/2012/03 SAS PIERRE FABRE pentru soluţie perfuzabilă NAVELBINE 10 mg/1 ml, solution not available 0724/ PIERRE FABRE Навелбин 10 mg/ml концентрат за not available PIERRE FABRE инфузионен разтвор Navelbine, 10 mg/ml, koncentrat do not available R/1736 SAS PIERRE FABRE sporządzania roztworu do infuzji Navelbine 10 mg/ml concentrat not available 4661/2012/01 SAS PIERRE FABRE pentru soluţie perfuzabilă Навелбин 20 mg меки капсули not available PIERRE FABRE Navelbine 20 mg lágy kapszula not available OGYI-T-472 1/03 PIERRE FABRE Навелбин 30 mg меки капсули not available PIERRE FABRE Navelbine 30 mg lágy kapszula not available OGYI-T-4721/04 PIERRE FABRE Navelbine 30 mg mjúk hylki not available IS/1/03/135/02 PIERRE FABRE PHARMA Navelbine 80 mg mjúk hylki not available IS/1/03/135/04 PIERRE FABRE PHARMA GR GR LU BG PL BG HU BG HU IS IS EMA/795271/2017 Page 5/9
6 Navelbine 10 mg/ml not available PIERRE FABRE PHARMA IS innrennslisþykkni, lausn Navelbine 20 mg mjúk hylki not available IS/1/03/135/01 PIERRE FABRE PHARMA IS Navelbine 10 mg/ml infuusiokonsentraatti, liuosta varten NAVELBINE 20 mg kapseli, pehmeä NAVELBINE 30 mg kapseli, pehmeä NAVELBINE 40 mg kapseli, pehmeä NAVELBINE 80 mg kapseli, pehmeä NAVELBINE 10 mg / ml concentrate for solution for infusion not available PIERRE FABRE PHARMA FI not available PIERRE FABRE PHARMA FI not available PIERRE FABRE PHARMA FI not available PIERRE FABRE PHARMA FI not available PIERRE FABRE PHARMA FI not available PA 1287/001/005 PIERRE FABRE LIMITED / IE UK NAVELBINE 20 mg soft capsule not available PA 1287/001/001 PIERRE FABRE LIMITED IE NAVELBINE 30 mg soft capsule not available PA 1287/001/002 PIERRE FABRE LIMITED IE NAVELBINE 80 mg soft capsule not available PA 1287/001/004 PIERRE FABRE LIMITED / IE UK NAVELBINE 10 mg / 1 ml not available PIERRE FABRE PHARMA DE Konzentrat zur Herstellung einer Infusionslösung NAVELBINE 20 mg Weichkapseln not available PIERRE FABRE PHARMA DE NAVELBINE 30 mg Weichkapseln not available PIERRE FABRE PHARMA DE NAVELBINE 80 mg Weichkapseln not available PIERRE FABRE PHARMA DE EMA/795271/2017 Page 6/9
7 NAVELBINE 50 mg / 5 ml Konzentrat zur Herstellung einer Infusionslösung not available PIERRE FABRE PHARMA NAVELBINE 20 mg, capsule molle not available SAS PIERRE FABRE NAVELBINE 30 mg, capsule molle not available SAS PIERRE FABRE NAVELBINE 50 mg/5 ml, solution not available PIERRE FABRE NAVELBINE 10 mg/1 ml, solution not available SAS PIERRE FABRE NAVELBINE 10 mg/1 ml, solution not available SAS PIERRE FABRE NAVELBINE 50 mg/5 ml, solution not available SAS PIERRE FABRE NAVELBINE 50 mg/5 ml not available PIERRE FABRE IRICA, concentrado para solución para S.A. perfusión NAVELBINE 20 mg cápsulas blandas not available PIERRE FABRE IRICA, S.A. NAVELBINE 30 mg cápsulas blandas not available PIERRE FABRE IRICA, S.A. NAVELBINE 10 mg/ml concentrado not available PIERRE FABRE IRICA, para solución para perfusión S.A. Navelbine 10 mg/ml koncentratas not available /1/97/2874/001 SAS PIERRE FABRE infuziniam tirpalui NAVELBINE 20 mg minkštosios not available /1/97/2874/005 SAS PIERRE FABRE kapsulės DE ES ES ES ES EMA/795271/2017 Page 7/9
8 NAVELBINE 30 mg minkštosios not available /1/97/2874/006 SAS PIERRE FABRE kapsulės Navelbine 10 mg/ml koncentratas not available /1/97/2874/002 SAS PIERRE FABRE infuziniam tirpalui Navelbine 10 mg/ml koncentratas not available /1/97/2874/003 SAS PIERRE FABRE infuziniam tirpalui Navelbine 10 mg/ml koncentratas not available /1/97/2874/004 SAS PIERRE FABRE infuziniam tirpalui NAVELBINE 20 mg soft capsule not available PL 00603/0029 PIERRE FABRE LIMITED UK NAVELBINE 30 mg soft capsule not available PL 00603/0030 PIERRE FABRE LIMITED UK NAVELBINE 80 mg soft capsule not available PL 00603/0032 PIERRE FABRE LIMITED UK NAVELBINE 10 mg/ml not available PL 00603/0028 PIERRE FABRE LIMITED UK concentrate for solution for infusion NAVELBINE 20 mg pehmekapsel not available SAS PIERRE FABRE EE NAVELBINE 30 mg pehmekapsel not available SAS PIERRE FABRE EE Navelbine, 10 mg/ml not available SAS PIERRE FABRE EE infusioonilahuse kontsentraat Navelbine 10 mg - not available SAS PIERRE FABRE Infusionskonzentrat Navelbine 20 mg - Kapseln not available PIERRE FABRE Navelbine 30 mg - Kapseln not available PIERRE FABRE Navelbine 80 mg - Kapseln not available PIERRE FABRE Navelbine 40 mg - Infusionskonzentrat not available PIERRE FABRE EMA/795271/2017 Page 8/9
9 Navelbine 50 mg - Infusionskonzentrat not available PIERRE FABRE Navelbine 10mg/ml, concentrate for not available GREGORIS solution for infusion HADJIGREGORIOU D NAVELBINE ORAL 20 mg mäkké not available 44/0131/02-S PIERRE FABRE kapsuly NAVELBINE ORAL 30 mg mäkké not available 44/0132/02-S PIERRE FABRE kapsuly NAVELBINE 10 mg infúzny not available 44/0136/92-S PIERRE FABRE koncentrát NAVELBINE 80 mg capsules, zacht not available RVG PIERRE FABRE NAVELBINE 10 mg/ml, concentraat not available RVG SAS PIERRE FABRE voor oplossing voor infusie NAVELBINE 30 mg capsules, zacht not available RVG PIERRE FABRE NAVELBINE 20 mg capsules, zacht not available RVG SAS PIERRE FABRE NAVELBINE koncentrát pro infuzní not available 44/ 136/ 92-S/C PIERRE FABRE roztok NAVELBINE ORAL 20 mg Měkké not available 44/238/02-C PIERRE FABRE tobolky NAVELBINE ORAL 30 mg Mekké not available 44/239/02-C PIERRE FABRE tobolky CY SK SK SK NL NL NL NL CZ CZ CZ EMA/795271/2017 Page 9/9
List of nationally authorised medicinal products
11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place
More informationPackage leaflet: Information for the user. Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine
Package leaflet: Information for the user Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine Read all of this leaflet carefully before you start using this medicine
More informationList of nationally authorised medicinal products
28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30
More informationList of nationally authorised medicinal products
6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user < Invented Name > 10 mg/ml concentrate for solution for infusion (50 mg/ 5 ml, 150 mg/15 ml, 450 mg/45 ml and 600 mg/60 ml) carboplatin Read all of this leaflet
More informationList of nationally authorised medicinal products
12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion
PACKAGE LEAFLET: INFORMATION FOR THE USER ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using this medicine.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide 20 mg/ml Concentrate for Solution for Infusion Etoposide
PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Keep this leaflet. You may
More informationList of nationally authorised medicinal products
5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30
More informationList of nationally authorised medicinal products
11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14
More informationList of nationally authorised medicinal products
13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London
More informationPackage leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion
Package leaflet: Information for the user ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using
More informationList of nationally authorised medicinal products
21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPackage Leaflet: Information For The User. Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion irinotecan hydrochloride trihydrate
Package Leaflet: Information For The User Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion irinotecan hydrochloride trihydrate The name of your medicine is Irinotecan Hydrochloride
More informationList of nationally authorised medicinal products
17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN)
PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN) Read all of this leaflet carefully before you are given Oxaliplatin. - Keep this leaflet. You
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20
More informationIrinotecan hydrochloride 20 mg/ml Concentrate For Solution for Infusion Irinotecan hydrochloride trihydrate
Irinotecan hydrochloride 20 mg/ml Concentrate For Solution for Infusion Irinotecan hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because it contains important
More informationList of nationally authorised medicinal products
08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationPackage leaflet: Information for the patient. Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie
Package leaflet: Information for the patient Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie Landiolol hydrochloride This medicine is subject to additional
More informationList of nationally authorised medicinal products
10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationList of nationally authorised medicinal products
30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place
More informationList of nationally authorised medicinal products
28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf
More informationPackage leaflet: Information for the user. Paclitaxel 6 mg/ml, Concentrate for Solution for Infusion. Paclitaxel
Package leaflet: Information for the user Paclitaxel 6 mg/ml, Concentrate for Solution for Infusion Paclitaxel Read all of this leaflet carefully before you start using this medicine because it contains
More informationList of nationally authorised medicinal products
11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30
More informationPackage leaflet: Information for the user. Pemetrexed CF 25 mg/ml, concentraat voor oplossing voor infusie Pemetrexed
Package leaflet: Information for the user Pemetrexed CF 25 mg/ml, concentraat voor oplossing voor infusie Pemetrexed Read all of this leaflet carefully before you start receiving this medicine because
More informationList of nationally authorised medicinal products
29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPackage leaflet: Information for the user. Oxaliplatin 5 mg/ml, concentrate for solution for infusion. Oxaliplatin
Package leaflet: Information for the user Oxaliplatin 5 mg/ml, concentrate for solution for infusion Oxaliplatin Read all of this leaflet carefully before you start using this medicine because it contains
More informationPackage Leaflet: Information For The User. Metotrexat Accord 100 mg/ml concentrate for solution for infusion Methotrexate
Package Leaflet: Information For The User Metotrexat Accord 100 mg/ml concentrate for solution for infusion Methotrexate Read all of this leaflet carefully before you start using this medicine because
More information(DK/H/1774/001/R/001 Response on add CMS comments FRAR) OXALIPLATIN 150 MG; 50 MG POWDER FOR SOLUTION FOR INFUSION
Sandoz Business use only Page 1 of 10 Package leaflet: Information for the patient Oxaliplatin Ebewe 5mg/ml powder for solution for infusion Oxaliplatin Read all of this leaflet carefully before you are
More informationList of nationally authorised medicinal products
12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU
More informationPackage leaflet: Information for the user. Powder for concentrate for Solution for Infusion Ceftobiprolee
PACKAGE LEAFLET 1 Zevtera 500 mg Powder for concentrate for Solution for Infusion Ceftobiprolee Read all of this leaflet carefully before you start using this medicine because it contains important informationn
More informationPackage leaflet: Information for the patient. Zemplar 1 microgram capsules, soft paricalcitol
Package leaflet: Information for the patient Zemplar 1 microgram capsules, soft paricalcitol Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPackage leaflet: Information for the user Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabine phosphate
Package leaflet: Information for the user Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion Fludarabine phosphate The name of your medicine is Fludarabine phosphate 25 mg/ml
More informationList of nationally authorised medicinal products
12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711
More informationAPO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults
APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults Package Leaflet: Information for the User Read all of this leaflet carefully before you
More informationList of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationVersion: 0005 February 2008 powder for solution for infusion Replaces: 0004 July 2007 PACKAGE LEAFLET: INFORMATION FOR THE USER
Page: 1 Package Leaflet PACKAGE LEAFLET: INFORMATION FOR THE USER powder for solution for infusion Oxaliplatin Read all of this leaflet carefully before you start using this
More informationList of nationally authorised medicinal products
12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using
More informationPackage leaflet: Information for the user. Gemcitabine 40 mg/ml concentrate for solution for infusion. Gemcitabine
Package leaflet: Information for the user Gemcitabine 40 mg/ml concentrate for solution for infusion Gemcitabine Read all of this leaflet carefully before you start using this medicine because it contains
More informationPackage leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride
Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary
More informationPackage Leaflet: Information for the user. Caspofungin Clonmel 50 mg powder for concentrate for solution for infusion. Caspofungin
Package Leaflet: Information for the user Caspofungin Clonmel 50 mg powder for concentrate for solution for infusion Caspofungin Read all of this leaflet carefully before you or your child are given this
More informationPackage Leaflet: information for the patient
Package Leaflet: information for the patient Mymicyas 50 mg Powder for Concentrate for Solution for Infusion Mymicyas 70 mg Powder for Concentrate for Solution for Infusion caspofungin Read all of this
More informationInitial (Full) Marketing Authorisation application accelerated assessment timetables
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
More informationPackage leaflet:information for the patient. Zemplar 2 micrograms capsules, soft paricalcitol
Package leaflet:information for the patient Zemplar 2 micrograms capsules, soft paricalcitol Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationList of nationally authorised medicinal products
6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user 50 mg, poeder voor concentraat voor oplossing voor infusie 70 mg, poeder voor concentraat voor oplossing voor infusie Caspofungin Read all of this leaflet carefully
More informationImplementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO
Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
31 May 2018 EMA/CHMP/258276/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg productspecific bioequivalence
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Naloxone 400 micrograms/ml solution for injection/infusion. naloxone hydrochoride
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Naloxone 400 micrograms/ml solution for injection/infusion naloxone hydrochoride Read all of this leaflet carefully before this medicine is administered to
More informationPackage leaflet: Information for the patient. Ropivacaine 2 mg/ml solution for infusion in administration system. Ropivacaine hydrochloride
Package leaflet: Information for the patient Ropivacaine 2 mg/ml solution for infusion in administration system Ropivacaine hydrochloride Read all of this leaflet carefully before this medicine is given
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London
More informationEUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008
European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium
More informationPATIENT INFORMATION LEAFLET. Midazolam 5 mg/ml Solution for Injection or Infusion midazolam
PATIENT INFORMATION LEAFLET Midazolam 1 mg/ml Solution for Injection or Infusion Midazolam 5 mg/ml Solution for Injection or Infusion midazolam Read all of this leaflet carefully before you start taking
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More informationPublic administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective
Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government
More informationVARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014
Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More informationSANDIMMUN 50mg/ml Concentrate for solution for infusion. Sandimmun 50 mg/ml Concentrate for solution for infusion
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State EU/EEA Marketing authorisation
More informationEuropean Union herbal monograph on Pistacia lentiscus L., resin (mastix)
7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union
More informationScreening programmes for Hepatitis B/C in Europe
Programme STI, HIV/AIDS and viral hepatitis Screening programmes for Hepatitis B/C in Europe Mika Salminen, Ph.D. European Centre for Disease Prevention and Control Why might screening be needed for hepatitis
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationEuropean Medicines Agency decision
EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)
More informationEuropean Union herbal monograph on Peumus boldus Molina, folium
22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party
More informationEuropean Union herbal monograph on Eschscholzia californica Cham., herba
28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European
More informationEuropean Medicines Agency decision
EMA/281879/2015 European Medicines Agency decision P/0097/2015 of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human
More informationEuropean Medicines Agency decision
EMA/156109/2018 European Medicines Agency decision P/0103/2018 of 19 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for plazomicin (sulfate) (EMEA-001639-PIP02-17)
More informationEuropean Medicines Agency decision
EMA/38339/2017 European Medicines Agency decision P/0021/2017 of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA- 001501-PIP02-13-M02)
More informationEuropean Medicines Agency decision
EMA/120432/2017 European Medicines Agency decision P/0069/2017 of 3 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP01-13-M04) in
More information(Invented) Name Strength Pharmaceutical form. 70 mg And 1 mcg. Valebo 70 mg + 1 microgram Tabletten + capsules, zacht.
Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, applicant in the Member States 1 Member State EU/EEA Applicant company name, address
More information